Cargando…
WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
In recent years, with the rise of immunotherapeutic agents for cancer treatment, we have observed a paradigm shift in oncology drug development. One common problem accompanying such paradigm shifts is how to build research strategies to fit the mechanism of action of the newer compounds. Developing...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679210/ https://www.ncbi.nlm.nih.gov/pubmed/26715941 http://dx.doi.org/10.3332/ecancer.2015.604 |